Enliven Therapeutics Inc (ELVN)
24.02
+0.21
(+0.88%)
USD |
NASDAQ |
May 20, 16:00
24.02
0.00 (0.00%)
After-Hours: 19:27
Enliven Therapeutics Shareholders Equity (Quarterly): 317.71M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 317.71M |
| December 31, 2023 | 245.91M |
| September 30, 2023 | 261.75M |
| June 30, 2023 | 278.99M |
| Date | Value |
|---|---|
| March 31, 2023 | 291.42M |
| December 31, 2022 | -76.82M |
| September 30, 2022 | -68.10M |
| December 31, 2021 | -42.89M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-76.82M
Minimum
Dec 2022
317.71M
Maximum
Mar 2024
151.00M
Average
253.83M
Median
Shareholders Equity (Quarterly) Benchmarks
| Eyenovia Inc | 1.818M |
| Phathom Pharmaceuticals Inc | -148.50M |
| Lantern Pharma Inc | 35.77M |
| Vincerx Pharma Inc | -0.622M |
| NKGen Biotech Inc | -58.69M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 342.78M |
| Total Liabilities (Quarterly) | 25.06M |